(Q46897348)

26 December 2017

title

Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy (English)

1 reference

26 December 2017

0 references

1 reference

2

1 reference

26 December 2017

author name string

Giovanni B Frisoni

1

1 reference

26 December 2017

Cristina Geroldi

3

1 reference

26 December 2017

Barbara Brignoli

4

1 reference

26 December 2017

Livio Anglani

5

1 reference

26 December 2017

Samantha Galluzzi

6

1 reference

26 December 2017

Valeria Zacchi

7

1 reference

26 December 2017

Orazio Zanetti

8

1 reference

26 December 2017

publication date

1 October 2007

1 reference

26 December 2017

Aging Clinical and Experimental Research

published in

1 reference

26 December 2017

volume

19

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

349-355

1 reference

26 December 2017

Evidence-based pharmacotherapy of Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

NICE proposes to withdraw Alzheimer's drugs from NHS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Drug prescription in mild cognitive impairment: the physicians' perspective in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Rivastigmine in frontotemporal dementia: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Doctors and drug companies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Interactions between physicians and the health care technology industry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

Rational use of benzodiazepines in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324714

21 January 2018

Identifiers

DOI

10.1007/BF03324714

1 reference

26 December 2017

1 reference

26 December 2017